

<b>UC San Diego</b> <b>INSTITUTIONAL REVIEW BOARD ADMINISTRATION</b>	<b>OIA-419 CHECKLIST: Waiver of the Consent Process for Emergency Research</b>		
	NUMBER	DATE	PAGE
	OIA-419	09/06/2023	1 of 2
<p>The purpose of this checklist is to provide support for IRB members or the <u>designated reviewer</u> following the <i>OIA-314 WORKSHEET: Criteria for Approval and Additional Considerations</i>, or equivalent, when <u>research</u> involves waiver of consent for planned emergency <u>research</u>. This checklist, or equivalent, may be used for all reviews (initial, continuing, amendment, review by the convened IRB, and review using the expedited procedure). It does not need to be completed or retained.</p>			
<b>IRB Number:</b>			
<b>Investigator:</b>			
<b>1 Waiver of the Informed Consent Process for Planned Emergency Research<sup>1,2</sup> (Check if “Yes” or “N/A.” All must be checked)</b>			
<input type="checkbox"/>	The <u>research</u> is <b>NOT</b> subject to regulation by a Common Rule agency other than Department of Health and Human Services (DHHS) or Department of Defense (DOD).		
<input type="checkbox"/>	The <u>research</u> does <b>NOT</b> involve <u>prisoners</u> as subjects.		
<input type="checkbox"/>	The <u>research</u> does <b>NOT</b> involve pregnant subjects, fetuses, non-viable neonates, or neonates of uncertain viability.		
<input type="checkbox"/>	The IRB has reviewed and approved consent procedures and a consent document in accordance with <i>OIA-314 WORKSHEET: Criteria for Approval and Additional Considerations</i> , or equivalent.		
<input type="checkbox"/>	The <u>human subjects</u> are in a life-threatening situation. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Available treatments are unproven or unsatisfactory. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	The collection of valid scientific evidence, which may include evidence obtained through randomized placebo-controlled investigations, is necessary to determine the safety and effectiveness of particular <u>interventions</u> . <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Obtaining informed consent is not feasible because the subjects will not be able to give their informed consent as a result of their medical condition. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Obtaining informed consent is not feasible because the <u>intervention</u> under investigation must be administered before consent from the subjects' legally authorized representatives (LAR) is feasible. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Obtaining informed consent is not feasible because there is no reasonable way to identify prospectively the individuals likely to become eligible for participation in the <u>research</u> . <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Participation in the <u>research</u> holds out the prospect of direct benefit to the subjects because they are facing a life-threatening situation that necessitates <u>intervention</u> . <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Appropriate animal and other preclinical studies have been conducted, and the information derived from those studies and related evidence support the potential for the <u>intervention</u> to provide a direct benefit to the individual subject. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Risks associated with the investigation are reasonable in relation to what is known about the medical condition of the potential class of subjects, the risks and benefits of standard therapy, if any, and what is known about the risks and benefits of the proposed <u>intervention</u> or activity. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	The <u>research</u> could not practicably be carried out without the waiver. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	The proposed investigational plan defines the length of the potential therapeutic window based on scientific evidence, and the investigator has committed to attempting to contact an LAR for each subject within that window of time and, if feasible, to asking the LAR contacted for consent within that window rather than proceeding without consent. The investigator will summarize efforts made to contact LARs and make this information available to the IRB at the time of continuing review. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Additional protections of the rights and welfare of the subjects will include consultation (including, where appropriate, consultation carried out by the IRB) with representatives of the communities in which the <u>research</u> will be conducted and from which the subjects will be drawn. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Additional protections of the rights and welfare of the subjects will include public disclosure to the communities in which the <u>research</u> will be conducted and from which the subjects will be drawn, prior to initiation of the <u>research</u> , of plans for the investigation and its risks and expected benefits.		

<sup>1</sup> 21 CFR 50.24

<sup>2</sup> [Informed Consent Requirements in Emergency Research \(OPRR Letter, 1996\)](#)

UC San Diego INSTITUTIONAL REVIEW BOARD ADMINISTRATION	OIA-419 CHECKLIST: Waiver of the Consent Process for Emergency Research		
	NUMBER	DATE	PAGE
	OIA-419	09/06/2023	2 of 2
<input type="checkbox"/>	<i>Provide protocol specific findings justifying this determination:</i> Additional protections of the rights and welfare of the subjects will include public disclosure of sufficient information following completion of the <u>research</u> to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Additional protections of the rights and welfare of the subjects will include establishment of an independent data monitoring committee to exercise oversight of the <u>research</u> . <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	If obtaining informed consent is not feasible and an LAR is not reasonably available, the investigator has committed, if feasible, to attempting to contact, within the therapeutic window, the subject's family member who is not an LAR, and asking whether he or she objects to the subject's participation in the <u>research</u> . The investigator will summarize efforts made to contact family members and make this information available to the IRB at the time of continuing review. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	Procedures are in place to inform, at the earliest feasible opportunity, each subject, or if the subject remains incapacitated, an LAR of the subject, or if such a representative is not reasonably available, a family member, of the subject's inclusion in the <u>research</u> , the details of the investigation and other information contained in the informed consent document. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	There is a procedure to inform the subject, or if the subject remains incapacitated, an LAR of the subject, or if such a representative is not reasonably available, a family member, that he or she may discontinue the subject's participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	If an LAR or family member is told about the <u>research</u> and the subject's condition improves, the subject is also to be informed as soon as feasible. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	If a subject is entered into the <u>research</u> with waived consent and the subject dies before an LAR or family member can be contacted, information about the <u>research</u> is to be provided to the subject's LAR or family member, if feasible. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	The investigator will interpret "family member" to mean any one of the following legally competent persons: spouses; parents; <u>children</u> (including adopted <u>children</u> ); brothers, sisters, and spouses of brothers and sisters; and any individual related by blood or affinity whose close association with the subject is the equivalent of a family relationship. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	The IRB has reviewed and approved procedures and information to be used when providing an opportunity for a family member to object to a subject's participation in the <u>research</u> consistent with this waiver. <i>Provide protocol specific findings justifying this determination:</i>		
<input type="checkbox"/>	If the <u>research</u> is Food and Drug Administration (FDA)-regulated, the protocol is being performed under a separate investigational new drug application (IND) or investigational device exemption (IDE) that clearly identifies this protocol as including subjects who are unable to consent. <b>("N/A" if not FDA-regulated)</b>		
<input type="checkbox"/>	If the <u>research</u> is FDA-regulated, a licensed physician who is a member of or consultant to the IRB and who is not otherwise participating in the <u>research</u> has concurred with the above findings. <b>("N/A" if not FDA-regulated)</b>		
<input type="checkbox"/>	If the <u>research</u> is subject to DOD regulations, the Secretary of Defense must approve a waiver of the advance informed consent provision of <a href="#">10 USC 980</a> .		
<input type="checkbox"/>	If the <u>research</u> is NOT FDA-regulated, the <u>research</u> is not subject to regulations codified by the FDA at title <a href="#">21 CFR part 50</a> . <b>("N/A" if FDA-regulated)</b>		
If an IRB determines that it cannot approve a protocol because it does not meet the criteria in the exception or because of other relevant ethical concerns, the IRB must document its findings and provide these findings in writing promptly (within 30 days) to the investigator and the sponsor.			